Home/Filings/4/0001470831-25-000353
4//SEC Filing

Kumar Neil 4

Accession 0001470831-25-000353

CIK 0001743881other

Filed

Nov 17, 7:00 PM ET

Accepted

Nov 18, 7:31 PM ET

Size

18.2 KB

Accession

0001470831-25-000353

Insider Transaction Report

Form 4
Period: 2025-11-16
Kumar Neil
DirectorChief Executive Officer
Transactions
  • Tax Payment

    Common Stock

    2025-11-16$66.39/sh32,855$2,181,243254,932 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-11-1633,544167,720 total
    Common Stock (33,544 underlying)
  • Exercise/Conversion

    Common Stock

    2025-11-16+33,544256,634 total
  • Exercise/Conversion

    Common Stock

    2025-11-16+19,599276,233 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-11-1619,599176,394 total
    Common Stock (19,599 underlying)
  • Exercise/Conversion

    Common Stock

    2025-11-16+11,554287,787 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-11-1611,554150,199 total
    Common Stock (11,554 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    795,686
  • Common Stock

    (indirect: By Trust)
    4,598,447
Footnotes (6)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  • [F2]Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,697 shares of Common Stock underlying the Reporting Person's RSUs.
  • [F3]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  • [F4]The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
  • [F5]The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
  • [F6]The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Issuer

BridgeBio Pharma, Inc.

CIK 0001743881

Entity typeother

Related Parties

1
  • filerCIK 0001742485

Filing Metadata

Form type
4
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 7:31 PM ET
Size
18.2 KB